Literature DB >> 21051857

The Cain and Abl of epithelial-mesenchymal transition and transforming growth factor-β in mammary epithelial cells.

Tressa M Allington1, William P Schiemann.   

Abstract

Transforming growth factor-β (TGF-β) normally inhibits breast cancer development by preventing mammary epithelial cell (MEC) proliferation, by inducing MEC apoptosis, and by creating cell microenvironments that maintain MEC homeostasis and prevent their uncontrolled growth and motility. Mammary tumorigenesis elicits dramatic alterations in MEC architecture and microenvironment integrity, which collectively counteract the tumor-suppressing activities of TGF-β and enable its stimulation of breast cancer invasion and metastasis. How malignant MECs overcome the cytostatic actions imposed by normal microenvironments and TGF-β, and how abnormal microenvironments conspire with TGF-β to stimulate the development and progression of mammary tumors remains largely undefined. These knowledge gaps have prevented science and medicine from implementing treatments effective in simultaneously targeting abnormal cellular microenvironments, and in antagonizing the oncogenic activities of TGF-β in developing and progressing breast cancers. c-Abl is a ubiquitously expressed nonreceptor protein tyrosine kinase that essentially oversees all aspects of cell physiology, including the regulation of cell proliferation, migration and adhesion, as well as that of cell survival. Thus, the biological functions of c-Abl are highly reminiscent of those attributed to TGF-β, including the ability to function as either a suppressor or promoter of tumorigenesis. Interestingly, while dysregulated Abl activity clearly promotes tumorigenesis in hematopoietic cells, an analogous role for c-Abl in regulating solid tumor development, including those of the breast, remains controversial. Here, we review the functions of c-Abl in regulating breast cancer development and progression, and in alleviating the oncogenic activities of TGF-β and its stimulation of epithelial-mesenchymal transition during mammary tumorigenesis.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21051857      PMCID: PMC3245834          DOI: 10.1159/000320163

Source DB:  PubMed          Journal:  Cells Tissues Organs        ISSN: 1422-6405            Impact factor:   2.481


  102 in total

1.  Activated Abl kinase inhibits oncogenic transforming growth factor-beta signaling and tumorigenesis in mammary tumors.

Authors:  Tressa M Allington; Amy J Galliher-Beckley; William P Schiemann
Journal:  FASEB J       Date:  2009-08-18       Impact factor: 5.191

2.  X-linked inhibitor of apoptosis protein and its E3 ligase activity promote transforming growth factor-{beta}-mediated nuclear factor-{kappa}B activation during breast cancer progression.

Authors:  Jason R Neil; Maozhen Tian; William P Schiemann
Journal:  J Biol Chem       Date:  2009-06-15       Impact factor: 5.157

Review 3.  Imatinib mesylate for the treatment of chronic myeloid leukemia.

Authors:  Simona Soverini; Giovanni Martinelli; Ilaria Iacobucci; Michele Baccarani
Journal:  Expert Rev Anticancer Ther       Date:  2008-06       Impact factor: 4.512

4.  DNA mismatch repair-dependent activation of c-Abl/p73alpha/GADD45alpha-mediated apoptosis.

Authors:  Long Shan Li; Julio C Morales; Arlene Hwang; Mark W Wagner; David A Boothman
Journal:  J Biol Chem       Date:  2008-05-14       Impact factor: 5.157

5.  Role of c-Abl kinase in DNA mismatch repair-dependent G2 cell cycle checkpoint arrest responses.

Authors:  Mark W Wagner; Long Shan Li; Julio C Morales; Cristi L Galindo; Harold R Garner; William G Bornmann; David A Boothman
Journal:  J Biol Chem       Date:  2008-05-14       Impact factor: 5.157

Review 6.  Mechanisms of the epithelial-mesenchymal transition by TGF-beta.

Authors:  Michael K Wendt; Tressa M Allington; William P Schiemann
Journal:  Future Oncol       Date:  2009-10       Impact factor: 3.404

7.  p130Cas is required for mammary tumor growth and transforming growth factor-beta-mediated metastasis through regulation of Smad2/3 activity.

Authors:  Michael K Wendt; Jason A Smith; William P Schiemann
Journal:  J Biol Chem       Date:  2009-10-12       Impact factor: 5.157

8.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

Review 9.  Activated c-Abl tyrosine kinase in malignant solid tumors.

Authors:  J Lin; R Arlinghaus
Journal:  Oncogene       Date:  2008-04-07       Impact factor: 9.867

Review 10.  Transforming growth factor-beta in breast cancer: too much, too late.

Authors:  Mary Helen Barcellos-Hoff; Rosemary J Akhurst
Journal:  Breast Cancer Res       Date:  2009-02-26       Impact factor: 6.466

View more
  14 in total

1.  Discovery of Bivalent Kinase Inhibitors via Enzyme-Templated Fragment Elaboration.

Authors:  Frank E Kwarcinski; Michael E Steffey; Christel C Fox; Matthew B Soellner
Journal:  ACS Med Chem Lett       Date:  2015-07-13       Impact factor: 4.345

2.  Development of a highly selective c-Src kinase inhibitor.

Authors:  Kristoffer R Brandvold; Michael E Steffey; Christel C Fox; Matthew B Soellner
Journal:  ACS Chem Biol       Date:  2012-06-04       Impact factor: 5.100

Review 3.  The role of cytokines in breast cancer development and progression.

Authors:  Marcela Esquivel-Velázquez; Pedro Ostoa-Saloma; Margarita Isabel Palacios-Arreola; Karen E Nava-Castro; Julieta Ivonne Castro; Jorge Morales-Montor
Journal:  J Interferon Cytokine Res       Date:  2014-07-28       Impact factor: 2.607

4.  c-Abl-dependent molecular circuitry involving Smad5 and phosphatidylinositol 3-kinase regulates bone morphogenetic protein-2-induced osteogenesis.

Authors:  Nandini Ghosh-Choudhury; Chandi C Mandal; Falguni Das; Suthakar Ganapathy; Seema Ahuja; Goutam Ghosh Choudhury
Journal:  J Biol Chem       Date:  2013-07-02       Impact factor: 5.157

5.  Harnessing protein kinase A activation to induce mesenchymal-epithelial programs to eliminate chemoresistant, tumor-initiating breast cancer cells.

Authors:  Alex J Gooding; William P Schiemann
Journal:  Transl Cancer Res       Date:  2016-08       Impact factor: 1.241

6.  The role of EphB4 and IGF-IR expression in breast cancer cells.

Authors:  Gena Huang; Man Li
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

7.  Activation of abl family kinases in solid tumors.

Authors:  Sourik S Ganguly; Rina Plattner
Journal:  Genes Cancer       Date:  2012-05

8.  A phosphotyrosine switch determines the antitumor activity of ERβ.

Authors:  Bin Yuan; Long Cheng; Huai-Chin Chiang; Xiaojie Xu; Yongjian Han; Hang Su; Lingxue Wang; Bo Zhang; Jing Lin; Xiaobing Li; Xiangyang Xie; Tao Wang; Rajeshwar R Tekmal; Tyler J Curiel; Zhi-Min Yuan; Richard Elledge; Yanfen Hu; Qinong Ye; Rong Li
Journal:  J Clin Invest       Date:  2014-06-24       Impact factor: 14.808

Review 9.  A roundabout way to cancer.

Authors:  Mimmi S Ballard; Lindsay Hinck
Journal:  Adv Cancer Res       Date:  2012       Impact factor: 6.242

10.  c-Abl and Arg are activated in human primary melanomas, promote melanoma cell invasion via distinct pathways, and drive metastatic progression.

Authors:  S S Ganguly; L S Fiore; J T Sims; J W Friend; D Srinivasan; M A Thacker; M L Cibull; C Wang; M Novak; D M Kaetzel; R Plattner
Journal:  Oncogene       Date:  2011-09-05       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.